Market Overview

UPDATE: JP Morgan Downgrades Underweight on Myriad Genetics on Risk/Reward

Share:
Related MYGN
Myriad Genetics' Latest Alliance To Boost GeneSight Reach
Benzinga's Top Upgrades, Downgrades For October 2, 2017
Myriad Genetics Will Ride High On The Success Of Its New Molecular Diagnostic Products In Future Years (Seeking Alpha)

JP Morgan reduced its rating on Myriad Genetics (NASDAQ: MYGN) from Neutral to Underweight while reiterating its $26 price target.

JP Morgan commented, "We see the investor debate in 2013 for Myriad Genetics (MYGN) as being between possible upside to earnings from continued share repurchases and the addition of BART (both of which we believe are already assumed by the Street), and downside risk from a Supreme Court ruling on the ACLU case, and to a lesser extent, Medicare reimbursement. Even if gene patentability is upheld, the company faces a patent cliff in 2018, beyond which the primary cash flow generator, the BRCA genes, will face competition. With that in mind, we believe that the risk/reward is unfavorable ahead of the SCOTUS ruling, which is likely to be a major overhang on the stock."

Myriad Genetics closed at $27.88 on Wednesday.

Latest Ratings for MYGN

DateFirmActionFromTo
Nov 2017Deutsche BankMaintainsHold
Nov 2017Morgan StanleyMaintainsUnderweight
Oct 2017Morgan StanleyMaintainsUnderweight

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!

Partner Center